Royal Bank of Canada Acquires 7,654 Shares of Evolent Health, Inc (EVH)
Royal Bank of Canada increased its holdings in shares of Evolent Health, Inc (NYSE:EVH) by 1,197.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,293 shares of the technology company’s stock after acquiring an additional 7,654 shares during the period. Royal Bank of Canada’s holdings in Evolent Health were worth $210,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. FMR LLC boosted its position in Evolent Health by 117.7% in the second quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after buying an additional 5,333,252 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Evolent Health by 7.5% in the second quarter. JPMorgan Chase & Co. now owns 5,438,126 shares of the technology company’s stock valued at $137,857,000 after buying an additional 379,185 shares in the last quarter. Vanguard Group Inc. boosted its position in Evolent Health by 48.9% in the second quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after buying an additional 1,237,941 shares in the last quarter. Riverbridge Partners LLC acquired a new position in Evolent Health in the second quarter valued at about $58,878,000. Finally, Blair William & Co. IL boosted its position in Evolent Health by 31.4% in the second quarter. Blair William & Co. IL now owns 2,185,695 shares of the technology company’s stock valued at $55,407,000 after buying an additional 522,874 shares in the last quarter. Institutional investors and hedge funds own 98.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/royal-bank-of-canada-acquires-7654-shares-of-evolent-health-inc-evh/1721135.html.
Evolent Health, Inc (EVH) opened at $12.15 on Thursday. Evolent Health, Inc has a 12-month low of $10.30 and a 12-month high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.
Evolent Health (NYSE:EVH) last announced its earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The company had revenue of $107.90 million for the quarter, compared to analyst estimates of $104.49 million. During the same period in the prior year, the business earned ($0.26) earnings per share. Evolent Health’s quarterly revenue was up 79.2% on a year-over-year basis. equities analysts forecast that Evolent Health, Inc will post -0.57 earnings per share for the current year.
A number of equities analysts have commented on EVH shares. Jefferies Group LLC restated a “buy” rating and issued a $28.00 price target on shares of Evolent Health in a research report on Wednesday, September 6th. SunTrust Banks, Inc. restated a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a research report on Friday, November 3rd. Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a research report on Thursday, November 2nd. Zacks Investment Research upgraded shares of Evolent Health from a “sell” rating to a “hold” rating in a research report on Monday, October 9th. Finally, Robert W. Baird restated a “buy” rating and issued a $25.00 price target on shares of Evolent Health in a research report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company’s stock. Evolent Health has an average rating of “Buy” and a consensus price target of $28.00.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc (NYSE:EVH).
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.